Objective:To systematically evaluate the effectiveness and safety of traditional Chinese medicine(TCM)in the treatment of posttransarterial chemoembolization(TACE)syndrome of primary liver cancer.Methods:CNKI,VIP data...Objective:To systematically evaluate the effectiveness and safety of traditional Chinese medicine(TCM)in the treatment of posttransarterial chemoembolization(TACE)syndrome of primary liver cancer.Methods:CNKI,VIP database,Wanfang database,CBM,PubMed,MEDLINE,and Cochrane library were retrieved,and the RCTs of Chinese medicine in the treatment of primary liver cancer TACE postoperative syndrome were included from the establishment of the database to March 2022.The Cochrane bias risk tool was used to evaluate the quality of included articles.RevMan 5.4 software was used for metaanalysis of outcome indicators and GRADEprofiler 3.6 software was used to evaluate the quality of evidence.Results:A total of 3992 patients were included in 44 studies.Metaanalysis results showed that compared with conventional western medicine treatment,combined Chinese medicine treatment could reduce the incidence of fever[RR=1.45,95%CI(1.09,1.92)],nausea and vomiting[RR=1.47,95%CI(1.10,1.95)],liver pain[RR=1.21,95%CI(1.02,1.43)];shorten the duration of fever[SMD=2.11.95%CI(1.43,2.79)],nausea and vomiting[SMD=1.67,95%CI(1.22,2.11)],hepatic pain[SMD=1.90,95%CI(1.30,2.51)],abdominal distension and pain[SMD=1.27,95%CI(0.75,1.79)],loose stool[SMD=2.30,95%CI(1.24,3.36)],constipation[SMD=2.18,95%CI(1.52,2.84)]after TACE,also it can improve patient quality of life[RR=0.73,95%CI(0.65,0.82)],clinical TCM syndrome[RR=0.73,95%CI(0.65,0.82)],shortterm efficacy[RR=0.75,95%CI(0.66,0.85)],oneyear survival rate[RR=0.87,95%CI(0.78,0.96)]and liver function and immune function.There was no significant difference in the incidence of abdominal distension and abdominal pain.Conclusion:Compared with only symptomatic western medicine after surgery,the combination of Chinese medicine has a significant effect and good safety in the treatment of postTACE syndrome.展开更多
[Objectives]To observe the clinical efficacy of Shenling Baizhu Powder in the treatment of primary nephrotic syndrome(PNS)featuring damp abundance due to splenic asthenia.[Methods]40 patients with PNS were randomly di...[Objectives]To observe the clinical efficacy of Shenling Baizhu Powder in the treatment of primary nephrotic syndrome(PNS)featuring damp abundance due to splenic asthenia.[Methods]40 patients with PNS were randomly divided into treatment group(n=19)and control group(n=21).In the treatment group and the control group,methylprednisolone tablets were taken orally and cytoxan(CTX)was given intravenously for treatment;in the treatment group,based on oral administration of methylprednisolone tablets and intravenous drip of cytoxan(CTX),oral administration of traditional Chinese medicine(addition and subtraction of Shenling Baizhu Powder)was added.Urine routine,24-hour urinary protein,renal function and serum albumin were re-examined after 4 weeks of treatment.[Results]The total effective rate of the treatment group was significantly higher than that of the control group(89.47%vs 61.90%,P<0.05).After treatment,both groups could effectively reduce the levels of 24-hour urinary protein(P<0.05),serum creatinine(P<0.05)and urea nitrogen(P<0.05),and increase the level of serum albumin(P<0.05),but the degree of improvement in the treatment group was significantly higher than that in the control group(P<0.05),and the difference was statistically significant(P<0.05).[Conclusions]Methylprednisolone combined with addition and subtraction of Shenling Baizhu Powder could effectively reduce urinary protein,improve edema symptoms,shorten the course of hormone use and reduce adverse reactions in the treatment of PNS featuring damp abundance due to splenic asthenia.展开更多
基金National Famous Veteran Traditional Chinese Medicine Expert Inheritance Studio Construction Project(No.Teaching of Traditional Chinese Medicine Letter[2022]No.75)"One Million"Talent Project for Inheritance and Innovation of Traditional Chinese Medicine(Qihuang Project)Qihuang Scholar(No.Chinese Medicine Education Letter[2018]No.284)。
文摘Objective:To systematically evaluate the effectiveness and safety of traditional Chinese medicine(TCM)in the treatment of posttransarterial chemoembolization(TACE)syndrome of primary liver cancer.Methods:CNKI,VIP database,Wanfang database,CBM,PubMed,MEDLINE,and Cochrane library were retrieved,and the RCTs of Chinese medicine in the treatment of primary liver cancer TACE postoperative syndrome were included from the establishment of the database to March 2022.The Cochrane bias risk tool was used to evaluate the quality of included articles.RevMan 5.4 software was used for metaanalysis of outcome indicators and GRADEprofiler 3.6 software was used to evaluate the quality of evidence.Results:A total of 3992 patients were included in 44 studies.Metaanalysis results showed that compared with conventional western medicine treatment,combined Chinese medicine treatment could reduce the incidence of fever[RR=1.45,95%CI(1.09,1.92)],nausea and vomiting[RR=1.47,95%CI(1.10,1.95)],liver pain[RR=1.21,95%CI(1.02,1.43)];shorten the duration of fever[SMD=2.11.95%CI(1.43,2.79)],nausea and vomiting[SMD=1.67,95%CI(1.22,2.11)],hepatic pain[SMD=1.90,95%CI(1.30,2.51)],abdominal distension and pain[SMD=1.27,95%CI(0.75,1.79)],loose stool[SMD=2.30,95%CI(1.24,3.36)],constipation[SMD=2.18,95%CI(1.52,2.84)]after TACE,also it can improve patient quality of life[RR=0.73,95%CI(0.65,0.82)],clinical TCM syndrome[RR=0.73,95%CI(0.65,0.82)],shortterm efficacy[RR=0.75,95%CI(0.66,0.85)],oneyear survival rate[RR=0.87,95%CI(0.78,0.96)]and liver function and immune function.There was no significant difference in the incidence of abdominal distension and abdominal pain.Conclusion:Compared with only symptomatic western medicine after surgery,the combination of Chinese medicine has a significant effect and good safety in the treatment of postTACE syndrome.
基金Natural Science Research Project of Guangxi University of Chinese Medicine(2015LX037).
文摘[Objectives]To observe the clinical efficacy of Shenling Baizhu Powder in the treatment of primary nephrotic syndrome(PNS)featuring damp abundance due to splenic asthenia.[Methods]40 patients with PNS were randomly divided into treatment group(n=19)and control group(n=21).In the treatment group and the control group,methylprednisolone tablets were taken orally and cytoxan(CTX)was given intravenously for treatment;in the treatment group,based on oral administration of methylprednisolone tablets and intravenous drip of cytoxan(CTX),oral administration of traditional Chinese medicine(addition and subtraction of Shenling Baizhu Powder)was added.Urine routine,24-hour urinary protein,renal function and serum albumin were re-examined after 4 weeks of treatment.[Results]The total effective rate of the treatment group was significantly higher than that of the control group(89.47%vs 61.90%,P<0.05).After treatment,both groups could effectively reduce the levels of 24-hour urinary protein(P<0.05),serum creatinine(P<0.05)and urea nitrogen(P<0.05),and increase the level of serum albumin(P<0.05),but the degree of improvement in the treatment group was significantly higher than that in the control group(P<0.05),and the difference was statistically significant(P<0.05).[Conclusions]Methylprednisolone combined with addition and subtraction of Shenling Baizhu Powder could effectively reduce urinary protein,improve edema symptoms,shorten the course of hormone use and reduce adverse reactions in the treatment of PNS featuring damp abundance due to splenic asthenia.
